Annotation Detail
Information
- Associated Genes
- FGFR2
- Associated Variants
- FGFR2 FGFR2-BICC1
- Associated Disease
- endometrial cancer
- Source Database
- CIViC Evidence
- Description
- Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1920
- Gene URL
- https://civic.genome.wustl.edu/links/genes/22
- Variant URL
- https://civic.genome.wustl.edu/links/variants/782
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Endometrial Cancer
- Evidence Direction
- Supports
- Drug
- Erdafitinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26324363
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Erdafitinib | Sensitivity | true |